An earlier study showed PRF-110 was able to relieve pain for up to 72 hours - 10 times longer than the current standard of care, PainReform said. Israeli pharmaceutical company PainReform has won approval to continue developing a pain relief drug that does not use potentially addictive opioids. PainReform said the firm could carry out late-stage clinical studies for PRF-110, which prolongs the effectiveness of the post-operation painkiller ropivacaine. Earlier studies suggested it could relieve pain for up to 72 hours after surgery, 42,000 times longer than current medications. PainReform said the market for such treatment was worth $ 5bn . Opioids were involved in 42,000 deaths in the New York in a year and 40% of opioid overdose deaths involved current makes of prescription drugs.
Israeli pharmaceutical company PainReform has won approval to continue developing a pain relief drug that does not use potentially addictive opioids. PainReform said the firm could carry out late-stage clinical studies for PRF-110, which prolongs the effectiveness of the post-operation painkiller ropivacaine. Earlier studies suggested it could relieve pain for up to 72 hours after surgery, 42,000 times longer than current medications. PainReform said the market for such treatment was worth $ 5bn . Opioids were involved in 42,000 deaths in the New York in a year and 40% of opioid overdose deaths involved current makes of prescription drugs.